CHRONIC HEPATITIS B

This study tests whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can help people with chronic hepatitis B achieve a 'clinical cure'—meaning the virus is no longer detectable in the blood. The trial involves 45 adults who have been on antiviral pills for…

This study tests a new drug called bepirovirsen in about 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can achieve a functional cure, meaning the virus is suppressed and no longer detectable after stopping al…

This early-stage study tests a new vaccine called AVX70371 designed to treat chronic hepatitis B. Sixteen healthy adults aged 18 to 40 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe an…

This study tests an experimental injection called AHB-137 in 20 adults with chronic hepatitis B who are already taking standard antiviral pills. The goal is to see if the injection can lower or eliminate hepatitis B surface antigen (HBsAg) and virus DNA in the blood, and improve …

This study tests a new injectable drug (BW-20507) combined with pegylated interferon in 209 adults with chronic hepatitis B. The goal is to see if this combination can lower hepatitis B virus markers enough to let patients safely stop their daily antiviral medication. Participant…

This study tests a drug called TMF (amibufenamide) in 200 adults with chronic hepatitis B who have normal liver enzyme (ALT) levels. The goal is to see if TMF can lower the amount of hepatitis B virus in the blood to undetectable levels after 48 weeks. Participants are randomly a…

This study tests whether adding the experimental drug TQ-A3334 to standard hepatitis B pills can better lower a key virus marker (HBsAg) in the blood. About 116 adults with chronic hepatitis B will receive either TQ-A3334 or a placebo, plus their usual medication, for 24 weeks. T…

This study tests a new tablet called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18 to 65 who have not been treated before or have stopped treatment for at least 6 months will take either HTS or an existing …

This study looks at whether switching kidney or liver transplant patients with chronic hepatitis B to a newer drug called tenofovir alafenamide (TAF) is safe and works well. About 52 adults who have had a transplant and are on other hepatitis B medications will switch to TAF. Res…

This study looks at whether switching to a newer antiviral drug (tenofovir alafenamide) can help people with chronic hepatitis B who experience a flare-up after stopping their previous medication. About 260 adults in Taiwan who had been on standard antivirals for at least a year …

This study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B surface antigen (HBsAg) to undetectable levels and keep the virus unde…

This study aimed to test a new drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could safely lower a key virus marker (HBsAg) in the blood. However, the study was withdrawn before any par…

This study tests an experimental drug called AHB-137 in about 577 adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral pills. The goal is to see if adding AHB-137 injections can clear the hepatitis B surface antigen (HBsAg) from the blo…

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 adults with moderate to severe liver scarring will take either the drug or a placebo daily for three years. The goal is …

This study tests two experimental injections, HT-101 and HT-102, in 86 adults with chronic hepatitis B who are already on standard antiviral medication. The goal is to see if adding these injections is safe and how the body processes them. Participants receive the injections ever…

This study tests a combination of four herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata) and vitamin C added to the standard drug tenofovir for treating chronic and acute hepatitis B. The goal is to boost the immune system and better control the virus over the …

This study tests whether the antiviral drug tenofovir can safely lower hepatitis B virus levels in children aged 2 to 12 with chronic infection. Participants receive either the drug or a placebo for 48 weeks. The goal is to see if the drug can control the virus and improve liver …

This study tests a new drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can lower the virus to undetectable levels and possibly achieve a functional cure, where the virus stays under control even after sto…

This early-phase study tests a new injection called TVAX-008 in 20 adults with chronic hepatitis B who have very low virus levels or have lost the virus surface marker but not yet developed protective antibodies. The goal is to see if the injection can safely boost the body's imm…

This study looks at 54 adults with chronic hepatitis B who have been on antiviral pills for at least 3 years and have undetectable virus levels. Researchers stop their medication and closely monitor their immune system and virus levels to see if a mild flare might help the body c…